WEBINAR | The Role of BAG3 in Dilated Cardiomyopathy
MAY 13, 8am PST
Join us May 13th for our next webinar about the role of BAG3 in dilated cardiomyopathy, presented by Dr. Arthur Feldman, Professor of Medicine at Temple University. Dilated cardiomyopathy (DCM) is a condition affecting more than 3 million US patients, many of whom develop DCM due to ischemic heart disease. Recently, subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM—one of those being the BAG3 gene. It is estimated that approximately 35,000 individuals in the United States have the disease-causing BAG3 haploinsufficiency, representing an orphan disease by FDA guidelines. Despite improvements in pharmacotherapy and care, the five year survival rate of a patient with DCM is only 50%. Dr. Feldman will discuss how the development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent progression of the disease in this otherwise healthy population of young adults. Dr. Feldman is an internationally renowned cardiologist who served as Executive Dean of the Temple University School of Medicine from 2011-2016. In 2016, he returned to the laboratory full-time and founded Renovacor Inc., a biotech company developing gene therapy for mono-genic causes of heart failure. Click here to register for his webinar.